Description
💊 Telmisartan 40mg + Cilnidipine 10mg + Chlorthalidone 12.5mg Tablet
Triple Action Power for Complete Hypertension Management
Introduction:
Telmisartan 40mg + Cilnidipine 10mg + Chlorthalidone 12.5mg is a fixed-dose triple combination antihypertensive formulated to provide comprehensive blood pressure control in patients with moderate to severe hypertension. This all-in-one therapy targets multiple pathways—vascular resistance, fluid retention, and sympathetic overactivity—offering a synergistic and long-lasting effect.
This triple therapy is particularly beneficial for patients who are inadequately controlled with dual therapy and require maximum efficacy with once-daily dosing.
Pharmacological Action:
-
Telmisartan 40mg – An angiotensin II receptor blocker (ARB) that:
-
Prevents vasoconstriction by blocking angiotensin II receptors
-
Reduces aldosterone levels, decreasing sodium and water retention
-
Offers cardiovascular and renal protection, especially in diabetic patients
-
-
Cilnidipine 10mg – A dual L/N-type calcium channel blocker that:
-
Inhibits L-type calcium channels causing vasodilation
-
Blocks N-type channels, reducing sympathetic nerve activity
-
Minimizes reflex tachycardia and protects renal function
-
-
Chlorthalidone 12.5mg – A long-acting thiazide-like diuretic that:
-
Promotes excretion of sodium and water
-
Reduces plasma volume and peripheral resistance
-
Has a prolonged duration of action (up to 72 hours) for sustained BP control
-
Therapeutic Uses:
-
Moderate to severe essential hypertension
-
Resistant hypertension (uncontrolled with dual therapy)
-
Hypertension with diabetes, obesity, or chronic kidney disease (CKD)
-
Patients with high cardiovascular risk
-
Suitable for step-up therapy or those needing multi-pathway BP control
Dosage and Administration:
-
One tablet once daily, preferably in the morning
-
May be taken with or without food
-
Should be swallowed whole with water
-
Regular monitoring of blood pressure, electrolytes, and renal function is advised
Key Benefits:
-
Triple mechanism for enhanced BP control
-
Once-daily dosage ensures 24-hour efficacy and improved compliance
-
Reduces risk of cardiovascular events like stroke and heart attack
-
Renal protective effects, especially beneficial in diabetics
-
Controls morning BP surge—a major trigger for cardiovascular events
-
Limits side effects seen with high doses of individual drugs
Common Side Effects:
-
Dizziness or lightheadedness
-
Fatigue or weakness
-
Increased urination
-
Ankle swelling (rare with Cilnidipine compared to other CCBs)
-
Muscle cramps
Serious but Rare Side Effects:
-
Electrolyte disturbances (low potassium, sodium)
-
Hypotension or fainting, especially in volume-depleted patients
-
Worsening renal function in at-risk populations
-
Allergic reactions or rash
-
Hyperuricemia or elevated blood glucose (from diuretic)
Precautions:
-
Not recommended during pregnancy or breastfeeding
-
Monitor in patients with renal or hepatic impairment
-
Avoid combining with other potassium-sparing agents or supplements
-
Alcohol may enhance hypotensive effect
-
Periodic monitoring of electrolytes, uric acid, and kidney function is essential
Storage:
-
Store at 15–30°C in a cool, dry place
-
Keep away from direct sunlight and moisture
-
Out of reach of children
Conclusion:
Telmisartan + Cilnidipine + Chlorthalidone offers a powerful, well-tolerated, and convenient triple therapy for difficult-to-control hypertension. It delivers multifaceted protection for the heart, kidneys, and arteries—making it an ideal choice for long-term cardiovascular risk reduction and better quality of life.
Note: This information is intended for educational purposes and should not replace professional medical advice. Always consult a healthcare provider for personalized guidance.
